Researchers Find Possible Trigger in Development of Type 1 Diabetes

JDRF-funded scientists from the Indiana University School of Medicine have found that a specific type of cellular stress takes place in pancreatic beta cells before the onset of type 1 diabetes and this stress response in the beta cell may in fact help ignite the autoimmune attack…. Read more

First US Artificial Pancreas Outpatient Trial Approved by FDA

The U.S. Food and Drug Administration (FDA) has approved the first outpatient artificial pancreas trial in the United States, marking a critical development in the effort by JDRF and its allies to bring this innovative and lifesaving diabetes technology to people with type 1 diabetes… Read more

KalVista and JDRF to Join Forces on New Treatments for Diabetic Eye Disease

KalVista Pharmaceuticals (“KalVista”) and JDRF have formed a research partnership focused on a novel approach being developed by KalVista to preserve vision and slow the progression of diabetic eye disease. Diabetic eye disease is one of the most common and most serious complications in people with type 1 diabetes (T1D). JDRF will provide up to $2.2 million inmilestone-based financial support and research expertise… Read more

Osiris Provides Update on Stem Cell Trial for Type 1 Diabetes

One year after Osiris Therapeutics in partnership with JDRF started the Phase 2 trial evaluating Prochymal, a formulation of adult mesenchymal stem cells (MSCs), in newly diagnosed type 1 diabetes patients, the company has released a statement providing an update on this groundbreaking trial. This first-of-its kind trial is… Read more

JDRF to Support Cell Therapy Research for Type 1 Diabetes

JDRF announced it will support a pioneering diabetes research program that is developing a first-of-its-kind cell therapy for type 1 diabetes and other forms of insulin-dependent diabetes. The therapy is a combination product that packages immature cells made from human embryonic stem cells (hESCs) that over time develop into mature pancreatic hormone producing cells… Read more

Diabetes’ JDRF Tries Shock Ad to Push the FDA

This is not a story about statistics, yet I have to start there. It is not a story about a shocking ad that ran in the New York Times and Washington Post, yet the uproar started there. This is the story of how … Read more

Subscribe to our Newsletter

Hide me